[Treatment of patients with hemophilia A having antibodies to factor VIII].
Four haemophiliacs with antibodies to factor VIII were treated on 7 occasions with fraction FEIBA. Satisfactory clinical results were achieved in patients receiving large doses of the preparation (63-105 units/kg). The administration of fraction FEIBA produced shortening of the whole blood clotting time but there was only a slight correction in the activated partial thromboplastin time. Two patients received prothrombin complex concentrate without clinical improvement in 1 case a good haemostatic effect was achieved after the infusion of cryoprecipitate and in 1 postoperative bleeding ceased with the administration of porcine factor VIII Immunosuppressive therapy with cyclophosphamide in 3 patients failed to prevent the anamnestic rise in antibody titer.
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D003451:Cryoprotective Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D011516:Prothrombin / Q000627:therapeutic use
D001323:Autoantibodies; D003451:Cryoprotective Agents; D003520:Cyclophosphamide; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX
Leczenie chorych z hemofilia A i przeciwciałami przeciw czynnikowi VIII.